loader image
Saturday, November 29, 2025
71.1 F
McAllen
- Advertisement -

A Simple Colonoscopy Can Save Your Life

Health & Lifestyle
334

Translate to Spanish or other 102 languages!

A routine screening for colorectal cancer beginning at age 45 can save lives! Image for illustration purposes
A routine screening for colorectal cancer beginning at age 45 can save lives! Image for illustration purposes

Mega Doctor News

- Advertisement -

By Texas Tech University Health Sciences Center El Paso

Newswise — A routine screening for colorectal cancer beginning at age 45 can save lives! In cancers that affect both men and women, colorectal cancer is the second leading cancer killer—but most cases can be prevented with routine screening tests.

Colorectal cancer usually starts from precancerous polyps in the colon or rectum. Over time, some polyps can turn into cancer.

- Advertisement -

Screening tests aid in finding precancerous polyps, so they can be removed before they turn into cancer. Screening tests can also find colorectal cancer early, when treatment works best.

- Advertisement -
- Advertisement -

Latest news

- Advertisement -
Previous article
Nursing Grad Gets a Life Lesson In Compassion
Next article
Let The Patient Choose Their Type 2 Diabetes Meds

More Articles

STHS Behavioral Hosting Webinar on Seasonal Depression, Dec. 4

Mega Doctor News It’s common for individuals to experience an emotional downturn during the winter...

AMA Adopts New Public Health Policies to Improve Health of the Nation

The American Medical Association (AMA) gathered physician and medical student leaders from all corners of medicine at its Interim Meeting of the House of Delegates to shape guiding policies on emerging health care topics.

Study Finds Best Strategy for Reducing Belly Fat

Over the last few years, research has shown that having excessive visceral fat — the fat surrounding the abdominal area that protects internal organs — can be detrimental to a person’s health.

FDA Approves Gene Therapy for Treatment of Spinal Muscular Atrophy

The U.S. Food and Drug Administration approved Itvisma (onasemnogene abeparvovec-brve) for the treatment of spinal muscular atrophy (SMA) in adult and pediatric patients 2 years of age and older with confirmed mutation in the survival motor neuron 1 (SMN1) gene. Itvisma is an adeno-associated virus (AAV) vector-based gene therapy.
- Advertisement -

We feature articles about leading professionals in the medical and healthcare industry in the South Texas area. We are your connection to the medical community!

Pick up a copy of our publication on more than 800 locations Valley-wide.

Contact Us

Office (956) 928-1255

Sales (956) 451-4585

info@tbbmega.com

sales@tbbmega.com

Subscribe

© Mega Doctor News 2025

×